Stoke Therapeutics, Inc.
NASDAQ:STOKBiotechnology
-$0.34 today
- Market cap
- $1.75B
- Beta
- 1.19
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$2.69
Volume 0.76M
Average 0.64M
STOK Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Stoke Therapeutics, Inc.NASDAQ: STOK
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $39.67M rose 21.4% year over year, behind the +45.7% change in trailing-twelve-month research & development. Sequentially, it fell 3.9% from the prior quarter. Over 3 fiscal years it compounded at +21.0% a year.
Context
- Research & development amounted to 74.8% of revenue in FY2025, down 169.0 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +21.4% toward the trailing-twelve-month pace of +45.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 137.92M USD
- Year-over-year change
- +54.7%
- 4-year CAGR
- +26.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 137.92M | +54.7% |
| FY2024 | 2024-12-31 | 89.13M | +8.4% |
| FY2023 | 2023-12-31 | 82.23M | +5.6% |
| FY2022 | 2022-12-31 | 77.84M | +43.7% |
| FY2021 | 2021-12-31 | 54.17M | — |
Research & Development vs competitors
How STOK compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +45.7% is the highest of 6, against a peer median of +12.6%.
- Research & development amounts to 449.1% of revenue for STOK, versus a peer median of 264.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $923.16M USD | +4.7% | +3.2% | 96.2% | |
| LTM Jun 2026 | $408.66M USD | +3.1% | +9.5% | 261.9% | |
| LTM Mar 2026 | $189.6M USD | +13.6% | +16.4% | 264.1% | |
| LTM Mar 2026 | $144.07M USD | +45.7% | +21.0% | 449.1% | |
| LTM Mar 2026 | $61.84M USD | — | +24.0% | 6710.8% | |
| LTM Mar 2026 | $58.13M USD | +16.8% | +6.7% | — | |
| LTM Mar 2026 | €44.34M EUR | +12.6% | -7.1% | 329.9% | |
| Peer median (excluding STOK) | — | +12.6% | +8.1% | 264.1% | |
Competitors are the stored peer set for STOK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 12.41M | 8.78M | 36.56M | 184.42M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 12.41M | 8.78M | 36.56M | 184.42M |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 54.17M | 77.84M | 82.23M | 89.13M | 137.92M |
| Selling, General & Admin | 31.9M | 38.92M | 41.32M | 48.79M | 67.09M |
| Operating Expenses | 86.07M | 116.76M | 123.55M | 137.93M | 205.01M |
| Depreciation & Amortization | 974K | 1.55M | 2.47M | 2.18M | 1.77M |
| EBITDA | (84.83M) | (99.52M) | (102.23M) | (86.8M) | (5.12M) |
| EBITDA Margin | — | -802.3% | -1164.4% | -237.5% | -2.8% |
| Operating Income | (86.07M) | (104.36M) | (114.77M) | (101.37M) | (20.59M) |
| Operating Margin | — | -841.2% | -1307.2% | -277.3% | -11.2% |
| Interest Income | 120K | 3.12M | 9.91M | 12.64M | 13.77M |
| Interest Expense | 0 | 0 | 0 | 0 | 9K |
| Other Income / Expenses | 260K | 3.29M | 10.07M | 12.39M | 13.71M |
| Income Before Tax | (85.81M) | (101.07M) | (104.7M) | (88.98M) | (6.89M) |
| Pre-Tax Margin | — | -814.7% | -1192.5% | -243.4% | -3.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (85.81M) | (101.07M) | (104.7M) | (88.98M) | (6.89M) |
| Net Margin | — | -814.7% | -1192.5% | -243.4% | -3.7% |
| EPS (Basic) | (2.34) | (2.60) | (2.38) | (1.65) | (0.12) |
| EPS (Diluted) | (2.34) | (2.60) | (2.38) | (1.65) | (0.12) |
| Weighted Avg Shares | 36.74M | 38.9M | 43.99M | 54.01M | 59.22M |
| Weighted Avg Shares (Diluted) | 36.74M | 38.9M | 43.99M | 54.01M | 59.22M |
Stoke Therapeutics, Inc.
NASDAQ:STOK
Intrinsic Alpha fair value
Locked
Current Price
$26.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.